A Meta-Analysis and Systematic Review of the Frequency, Clinicopathological Features, and Diagnostic Potential of CDH1 Methylation in Head and Neck Cancer.

IF 2.6 4区医学 Q3 CHEMISTRY, MEDICINAL

Anti-cancer agents in medicinal chemistry Pub Date : 2026-06-10 DOI:10.2174/0118715206420855251204072123

Mubarak Alqahtani, Abdulmohsin Mohammed Alzuhairi, Osama Hasan Alalmaie, Faisal Nasser Alahmari, Mohammed Nasser Alahmari, Madhawi Abdulaziz Alanazi, Yara Abdullah Alziyad, Mohammed Hamad Alqahtani, Noura Ali Alshahrani, Hossam Abdullah Alawdah, Abdulaziz Awad Alqarni, Faisal Mohammed Bin Libdah, Saud Nayef Salem Aldanyowi, Naif Yaseen Albar, Abdulsalam Mohammed Aleid

{"title":"A Meta-Analysis and Systematic Review of the Frequency, Clinicopathological Features, and Diagnostic Potential of CDH1 Methylation in Head and Neck Cancer.","authors":"Mubarak Alqahtani, Abdulmohsin Mohammed Alzuhairi, Osama Hasan Alalmaie, Faisal Nasser Alahmari, Mohammed Nasser Alahmari, Madhawi Abdulaziz Alanazi, Yara Abdullah Alziyad, Mohammed Hamad Alqahtani, Noura Ali Alshahrani, Hossam Abdullah Alawdah, Abdulaziz Awad Alqarni, Faisal Mohammed Bin Libdah, Saud Nayef Salem Aldanyowi, Naif Yaseen Albar, Abdulsalam Mohammed Aleid","doi":"10.2174/0118715206420855251204072123","DOIUrl":null,"url":null,"abstract":"Introduction: Head and neck cancer (HNC), particularly head and neck squamous cell carcinoma (HNSCC), is a major global health issue. Epigenetic alterations, especially the hypermethylation of tumor suppressor genes (TSGs) such as CDH1, which encodes the E-cadherin protein, play a crucial role in the development and progression of HNC. This meta-analysis aimed to evaluate the role of CDH1 methylation as a potential diagnostic and less invasive biomarker for HNC, assessing its correlation with various clinical, pathological, and lifestyle factors, including tumor size, lymph node involvement, clinical stage, smoking, and alcohol consumption.Methods: A systematic search was conducted across multiple databases (PubMed, Scopus, Web of Science, and Cochrane Library) up to September 2024. Studies that reported the frequency of CDH1 methylation in HNC patients and its association with clinicopathological factors were included. Statistical analysis was performed using Review Manager (RevMan 5.4) software, and diagnostic test accuracy (DTA) was assessed through sensitivity, specificity, and area under the curve (AUC) analyses using MetaDesk software.Results: Forty-three studies, involving 1542 HNC patients and 1532 controls, were included. The pooled analysis showed a significantly higher prevalence of CDH1 methylation in HNC patients compared to controls (OR = 8.09, 95% CI: 5.29-12.36, P < 0.001). Subgroup analysis revealed significant associations in both Asian and Caucasian populations and various tumor subtypes. CDH1 methylation correlated with alcohol consumption and advanced clinical stage, but not with tumor size, lymph node involvement, or metastatic status. The pooled diagnostic odds ratio was 8.18 (95% CI: 5.32-12.58), with an AUC of 0.78, indicating moderate diagnostic accuracy.Conclusion: CDH1 methylation holds promise as a diagnostic biomarker for HNC, demonstrating high specificity but moderate sensitivity. While its association with specific clinicopathological factors is notable, it should be used in conjunction with other diagnostic tools for more effective clinical application.","PeriodicalId":7934,"journal":{"name":"Anti-cancer agents in medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2026-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anti-cancer agents in medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0118715206420855251204072123","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Head and neck cancer (HNC), particularly head and neck squamous cell carcinoma (HNSCC), is a major global health issue. Epigenetic alterations, especially the hypermethylation of tumor suppressor genes (TSGs) such as CDH1, which encodes the E-cadherin protein, play a crucial role in the development and progression of HNC. This meta-analysis aimed to evaluate the role of CDH1 methylation as a potential diagnostic and less invasive biomarker for HNC, assessing its correlation with various clinical, pathological, and lifestyle factors, including tumor size, lymph node involvement, clinical stage, smoking, and alcohol consumption.

Methods: A systematic search was conducted across multiple databases (PubMed, Scopus, Web of Science, and Cochrane Library) up to September 2024. Studies that reported the frequency of CDH1 methylation in HNC patients and its association with clinicopathological factors were included. Statistical analysis was performed using Review Manager (RevMan 5.4) software, and diagnostic test accuracy (DTA) was assessed through sensitivity, specificity, and area under the curve (AUC) analyses using MetaDesk software.

Results: Forty-three studies, involving 1542 HNC patients and 1532 controls, were included. The pooled analysis showed a significantly higher prevalence of CDH1 methylation in HNC patients compared to controls (OR = 8.09, 95% CI: 5.29-12.36, P < 0.001). Subgroup analysis revealed significant associations in both Asian and Caucasian populations and various tumor subtypes. CDH1 methylation correlated with alcohol consumption and advanced clinical stage, but not with tumor size, lymph node involvement, or metastatic status. The pooled diagnostic odds ratio was 8.18 (95% CI: 5.32-12.58), with an AUC of 0.78, indicating moderate diagnostic accuracy.

Conclusion: CDH1 methylation holds promise as a diagnostic biomarker for HNC, demonstrating high specificity but moderate sensitivity. While its association with specific clinicopathological factors is notable, it should be used in conjunction with other diagnostic tools for more effective clinical application.

查看原文本刊更多论文

头颈癌中CDH1甲基化的频率、临床病理特征和诊断潜力的meta分析和系统综述

头颈癌（HNC），特别是头颈鳞状细胞癌（HNSCC），是一个主要的全球健康问题。表观遗传改变，特别是编码E-cadherin蛋白的肿瘤抑制基因（tsg）如CDH1的高甲基化，在HNC的发生和发展中起着至关重要的作用。本荟萃分析旨在评估CDH1甲基化作为HNC的潜在诊断和低侵入性生物标志物的作用，评估其与各种临床、病理和生活方式因素的相关性，包括肿瘤大小、淋巴结累及、临床分期、吸烟和饮酒。方法：系统检索截至2024年9月的多个数据库（PubMed、Scopus、Web of Science和Cochrane Library）。报告了HNC患者中CDH1甲基化的频率及其与临床病理因素的关联的研究被纳入。使用Review Manager （RevMan 5.4）软件进行统计分析，使用metaddesk软件通过敏感性、特异性和曲线下面积（AUC）分析评估诊断测试准确性（DTA）。结果：纳入43项研究，涉及1542例HNC患者和1532例对照。合并分析显示，与对照组相比，HNC患者的CDH1甲基化发生率显著更高（OR = 8.09, 95% CI: 5.29-12.36, P < 0.001）。亚组分析显示，亚洲和高加索人群与各种肿瘤亚型均有显著相关性。CDH1甲基化与饮酒和晚期临床阶段相关，但与肿瘤大小、淋巴结受累或转移状态无关。合并诊断优势比为8.18 (95% CI: 5.32-12.58)， AUC为0.78，表明诊断准确性中等。结论：CDH1甲基化有望作为HNC的诊断生物标志物，具有高特异性和中等敏感性。虽然它与特定的临床病理因素的关联是值得注意的，但它应该与其他诊断工具结合使用，以获得更有效的临床应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anti-cancer agents in medicinal chemistry ONCOLOGY-CHEMISTRY, MEDICINAL

CiteScore

5.10

自引率

3.60%

发文量

323

审稿时长

4-8 weeks

期刊介绍： Formerly: Current Medicinal Chemistry - Anti-Cancer Agents. Anti-Cancer Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in medicinal chemistry and rational drug design for the discovery of anti-cancer agents. Each issue contains a series of timely in-depth reviews and guest edited issues written by leaders in the field covering a range of current topics in cancer medicinal chemistry. The journal only considers high quality research papers for publication. Anti-Cancer Agents in Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in cancer drug discovery.